NDAORALTABLET
Approved
Mar 2013
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
3/8 — Basic
QUARTETTE (levonorgestrel/ethinyl estradiol and ethinyl estradiol) by Teva is ovulation. First approved in 2013.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QUARTETTE is an oral contraceptive tablet combining levonorgestrel (progestin) and ethinyl estradiol (estrogen) in a dynamic dosing regimen designed to suppress ovulation. It is indicated for pregnancy prevention in women of reproductive age. The product uses a unique quarterly dosing pattern to reduce hormone exposure while maintaining contraceptive efficacy.
LOE Approaching2.8 years to LOE
Product approaching loss of exclusivity in ~2.9 years signals defensive positioning; brand team focus shifting toward generic transition planning and market-share retention strategies.
Mechanism of Action
ovulation.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Worked on QUARTETTE at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.